Skip to content

Our Mission

At George Medicines our mission is to extend and improve the lives of the hundreds of millions of people suffering from the world’s leading causes of death and disability, such as cardiovascular disease and type 2 diabetes. We are developing novel, fixed, ultra-low-dose combinations of best-in-class existing treatments that we believe have the potential to reduce the impact of treatable, non-communicable diseases on patients, families, health systems and economies.

No.1 Fact

Fixed-dose combinations can be a valuable tool to improve therapy adherence in patients with hypertension, who are often prescribed multiple pills per day and have low rates of therapy adherence. Lower levels of adherence are associated with worse blood pressure control and adverse outcomes, including stroke, myocardial infarction, heart failure, and death.

About Us

George Medicines is a venture-backed spin-out company from George Health, initially established to commercialise the research of The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases.

We use the research base and scientific expertise of The George Institute to pursue the late-stage development of our fixed-dose combination therapies. We also use the commercial expertise of George Health and the infrastructure of George Clinical, the global clinical research organisation, for the formulation and clinical development of our portfolio.

We are backed by leading biotech venture capital investor Brandon Capital Partners, the largest life science healthcare fund in Australasia, whose expertise is directed toward supporting its portfolio companies along the path to commercialisation and the MRCF (Medical Research Commercialisation Fund) focused on taking the most promising medical discoveries into the latest medical therapies to save lives and improve quality of life, while generating returns for investors.


George Medicines Team

George Medicines is led by an experienced and respected team with a proven track record in pharmaceutical development and commercialisation, global health and the management of non-communicable diseases.

Management Team

Stefan König
Chief Executive Officer
Dr Karl Roberts
Chief Operating Officer
Professor Anthony Rodgers
Chief Medical Officer
Scott Featherston
Chief Financial Officer
Erin Corstanje
New Product Development Project Management Director

The Board

Professor Stephen MacMahon
Chairman (Founder & Board Director, George Health Principal Director, George Institute)
Mustapha Staph Leavenworth Bakali
Board Director
Ingmar Wahlqvist
Board Director
Dr Charmaine Gittleson
Non-executive director